6 results on '"Senti, G"'
Number of results to display per page
Search Results
2. Asthma caused by a pet bat.
- Author
-
Senti G, Lundberg M, and Wüthrich B
- Subjects
- Adult, Animals, Asthma immunology, Conjunctivitis etiology, Conjunctivitis immunology, Female, Humans, Immunoglobulin E analysis, Rhinitis, Allergic, Perennial etiology, Rhinitis, Allergic, Perennial immunology, Skin Tests, Allergens adverse effects, Animals, Domestic, Asthma etiology, Chiroptera, Feces, Tenebrio
- Published
- 2000
- Full Text
- View/download PDF
3. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies
- Author
-
Calderon, M. A., Demoly, P., Casale, T., Akdis, C. A., Bachert, C., Bewick, M., Bilo, B. M., Bohle, B., Bonini, S., Bush, A., Caimmi, D. P., Canonica, G. W., Cardona, V., Chiriac, A. M., Cox, L., Custovic, A., De Blay, F., Devillier, P., Didier, A., Di Lorenzo, G., Du Toit, G., Durham, S. R., Eng, P., Fiocchi, A., Fox, A. T., van Wijk, R. Gerth, Gomez, R. M., Haahtela, Tari Markku Kallevi, Halken, S., Hellings, P. W., Jacobsen, L., Just, J., Tanno, L. K., Kleine-Tebbe, J., Klimek, L., Knol, E. F., Kuna, P., Larenas-Linnemann, D. E., Linneberg, A., Matricardi, M., Malling, H. J., Moesges, R., Mullol, J., Muraro, A., Papadopoulos, N., Passalacqua, G., Pastorello, E., Pfaar, O., Price, D., Rodriguez del Rio, P., Rueff, R., Samolinski, B., Scadding, G. K., Senti, G., Shamji, M. H., Sheikh, A., Sisul, J. C., Sole, D., Sturm, G. J., Tabar, A., Van Ree, R., Ventura, M. T., Vidal, C., Varga, E. M., Worm, M., Zuberbier, T., Bousquet, J., Clinicum, and Department of Dermatology, Allergology and Venereology
- Subjects
EIP on AHA ,EAACI POSITION PAPER ,RUSH IMMUNOTHERAPY ,GRASS-POLLEN ALLERGY ,INTERNATIONAL CONSENSUS ,EUROPEAN INNOVATION PARTNERSHIP ,NATIONAL DATABASES ,ORAL IMMUNOTHERAPY ,Asthma ,Ageing ,AIRWAYS ICPs ,SUBLINGUAL IMMUNOTHERAPY ,PRECISION MEDICINE ,IMMUNOLOGY/PRACTALL CONSENSUS REPORT ,3121 General medicine, internal medicine and other clinical medicine ,Allergen immunotherapy ,Rhinitis - Abstract
Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing.
- Published
- 2016
4. Allergy immunotherapy across the life cycle to promote active and healthy ageing : from research to policies
- Author
-
Calderon, MA, Demoly, P, Casale, T, Akdis, CA, Bachert, C, Bewick, M, Bilo, BM, Bohle, B, Bonini, S, Bush, A, Caimmi, DP, Canonica, GW, Cardona, V, Chiriac, AM, Cox, L, Custovic, A, De Blay, F, Devillier, P, Didier, A, Di Lorenzo, G, Du Toit, G, Durham, SR, Eng, P, Fiocchi, A, Fox, AT, Van Wijk, RG, Gomez, RM, Haathela, T, Halken, S, Hellings, PW, Jacobsen, L, Just, J, Tanno, LK, Kleine-Tebbe, J, Klimek, L, Knol, EF, Kuna, P, Larenas-Linnemann, DE, Linneberg, A, Matricardi, M, Malling, HJ, Moesges, R, Mullol, J, Muraro, A, Papadopoulos, N, Passalacqua, G, Pastorello, E, Pfaar, O, Price, D, Rodriguez del Rio, P, Rueff, R, Samolinski, B, Scadding, GK, Senti, G, Shamji, MH, Sheikh, A, Sisul, JC, Sole, D, Sturm, GJ, Tabar, A, Van Ree, R, Ventura, MT, Vidal, C, Varga, EM, Worm, M, Zuberbier, T, Bousquet, J, Internal Medicine, and Medical Research Council (MRC)
- Subjects
Pulmonary and Respiratory Medicine ,EIP on AHA ,Science & Technology ,EAACI POSITION PAPER ,RUSH IMMUNOTHERAPY ,Allergy ,GRASS-POLLEN ALLERGY ,INTERNATIONAL CONSENSUS ,EUROPEAN INNOVATION PARTNERSHIP ,Immunology ,NATIONAL DATABASES ,ORAL IMMUNOTHERAPY ,Ageing ,AIRWAYS ICPs ,Allergen immunotherapy ,Asthma ,Rhinitis ,Immunology and Allergy ,SUBLINGUAL IMMUNOTHERAPY ,PRECISION MEDICINE ,IMMUNOLOGY/PRACTALL CONSENSUS REPORT ,Medicine and Health Sciences ,Life Sciences & Biomedicine - Abstract
European Innovation Partnership on Active and Healthy Ageing Reference Site MACVIA-France, European Structural and Development Funds of Region Languedoc Roussillon Allergic diseases often occur early in life and persist throughout life. This life-course perspective should be considered in allergen immunotherapy. In particular it is essential to understand whether this al treatment may be used in old age adults. The current paper was developed by a working group of AIRWAYS integrated care pathways for airways diseases, the model of chronic respiratory diseases of the European Innovation Partnership on active and healthy ageing (DG CONNECT and DG Sante). It considered (1) the political background, (2) the rationale for allergen immunotherapy across the life cycle, (3) the unmet needs for the treatment, in particular in preschool children and old age adults, (4) the strategic framework and the practical approach to synergize current initiatives in allergen immunotherapy, its mechanisms and the concept of active and healthy ageing. Imperial Coll London, Natl Heart & Lung Inst, Royal Brompton Hosp NHS, London, England UPMC Paris 06, Sorbonne Univ,Dept Pneumol & Addictol,UMR S 1136, Hop Arnaud de Villeneuve,CHRU Montpellier, IPLESP,Equipe EPAR,Unite Allergol, F-75013 Paris, France Univ S Florida, Morsani Coll Med, Tampa, FL USA Univ Zurich, Swiss Inst Allergy & Asthma Res SIAF, Christine Kuhne Ctr Allergy Res & Educ CK CARE, Davos, Switzerland Univ Hosp Ghent, ENT Dept, Upper Airways Res Lab URL, Ghent, Belgium IQ4U Consultants Ltd, London, England Osped Riuniti, Univ Hosp, Allergy Unit, Dept Internal Med, Ancona, Italy Med Univ Vienna, Dept Pathophysiol & Allergy Res, Ctr Pathophysiol Infectiol & Immunol, Vienna, Austria Univ Naples 2, Rome, Italy CNR, IFT, Rome, Italy Univ Genoa, Allergy & Resp Dis Clin, DIMI, IRCCS AOU San Martino IST, Genoa, Italy Hosp Univ Vall dHebron, Allergy Sect, Dept Internal Med, Barcelona, Spain Montpellier UPMC Univ Paris 06, Sorbonne Univ,UMRS 1136, Hop Arnaud de Villeneuve,Equipe EPAR IPLESP, Div Allergy,Dept Pulmonol,Univ Hosp Montpellier, Paris, France Nova Southeastern Univ, Ft Lauderdale, FL USA Univ Hosp Strasbourg, Div Allergy, Chest Dis Dept, Strasbourg, France Univ Versailles St Quentin, Suresnes, France Foch Hosp, Dept Airway Dis, Clin Pharmacol Unit, UPRES EA 220, Suresnes, France Rangueil Larrey Hosp, Dept Resp Dis, Toulouse, France Univ Palermo, Di Bi MIS, Palermo, Italy Kings Coll London, Guys & St Thomas NHS Trust, London, England Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Sect, London, England Childrens Hosp, Dept Pediat Pulmonol & Allergy, Aarau, Switzerland Bambino Gesu Pediat Hosp, Dept Pediat, Div Allergy, Rome, Italy Kings Coll London, Allergy Acad, London, England Erasmus MC, Dept Internal Med, Bldg Rochussenstr, Rotterdam, Netherlands Hosp San Bernardo, Unidad Alergia & Asma, Salta, Argentina Helsinki Univ Hosp, Skin & Allergy Hosp, Helsinki, Finland Odense Univ Hosp, Hans Christian Andersen Childrens Hosp, Odense, Denmark Katholieke Univ Leuven, Univ Hosp Leuven, Clin Dept Otorhinolaryngol Head & Neck Surg, Louvain, Belgium Secretary Immunotherapy Interest Grp EAACI, Allergy Learning & Consulting, Copenhagen, Denmark UPMC Univ Paris, Sorbonne Univ,Hop Enfants Armand Trousseau,INSERM, Inst Pierre Louis Epidemiol & Sante Publ,Equipe E, Allergol Dept,Ctr Asthme & Allergies,UMR S 1136, Paris, France Hosp Sirio Libanes, Sao Paulo, Brazil Univ Hosp Montpellier, Montpellier, France UPMC Paris 06, Sorbonne Univ, Equipe EPAR, UMR S 1136,IPLESP, Paris, France Ackermann Hanf & Kleine Tebbe, Outpatient Clin & Clin Res Ctr, Allergy & Asthma Ctr Westend, Berlin, Germany German Soc Otorhinolaryngol HNS, Ctr Rhinol & Allergol, Wiesbaden, Germany Univ Med Ctr Utrecht, Dept Immunol & Dermatol Allergol, Utrecht, Netherlands Med Univ Lodz, Lodz, Poland ARIA, Mexico City, DF, Mexico Hosp Med Sur, AAAAI, Mexico City, DF, Mexico Capital Reg Denmark, Res Ctr Prevent & Hlth, Copenhagen, Denmark Rigshosp, Dept Clin Expt Res, Copenhagen, Denmark Univ Copenhagen, Fac Hlth & Med Sci, Dept Clin Med, Copenhagen, Denmark Charite Med Univ, Pediat Pneumol & Immunol, Berlin, Germany Gentofte Univ Hosp, Allergy Clin, Danish Allergy Ctr, Hellerup, Denmark Klinikum Univ Koln AoR, IMSIE, Cologne, Germany Hosp Clin Barcelona, Unitat Rinol & Clin Olfacte, ENT Dept, Clin & Expt Resp Immunoallergy,IDIBAPS,CIBERES, Barcelona, Catalonia, Spain Padua Gen Univ Hosp, Dept Women & Child Hlth, Food Allergy Referral Ctr Veneto Reg, Padua, Italy Univ Athens, Allergy Unit, Pediat Clin 2, Athens, Greece Univ Genoa, Allergy & Resp Dis, IRCCS San Martino IST, Genoa, Italy ASST Grande Osped Metropolitano Niguarda, Pzza Osped Maggiore, Milan, Italy Univ Med Mannheim, Dept Otorhinolaryngol Head & Neck Surg, Mannheim, Germany Heidelberg Univ, Med Fac Mannheim, Heidelberg, Germany Ctr Rhinol & Allergol, Wiesbaden, Germany Univ Aberdeen, Acad Primary Care, Div Appl Hlth Sci, Primary Care Resp Med, Aberdeen, Scotland RiRL, Cambridge, England Optimum Patient Care Ltd, Singapore, Singapore Hosp Infantil Univ Nino Jesus, Allergy Sect, Madrid, Spain Ludwig Maximillian Univ, Dept Dermatol & Allergol, Munich, Germany Med Univ Warsaw, Dept Prevent Environm Hazards & Allergol, Warsaw, Poland Royal Natl Throat Nose & Ear Hosp, London, England UCL, London, England Univ Zurich Hosp, Clin Trials Ctr, Zurich, Switzerland Imperial Coll London, Natl Heart & Lung Inst, Allergy & Clin Immunol Inflammat Repair & Dev Sec, Immunomodulat & Tolerance Grp,Fac Med, London, England MRC, London, England Asthma UK Ctr Allerg Mechanisms Asthma, London, England Univ Edinburgh, Usher Inst Populat Hlth Sci & Informat, Asthma UK Ctr Appl Res, Med Informat Ctr, Teviot Pl, Edinburgh EH8 9AG, Midlothian, Scotland SLAAI, Asuncion, Paraguay Univ Fed Sao Paulo, Programa Posgrad Pediat & Ciencias Aplicadas Pedi, Dept Pediat EPM, Sao Paulo, Brazil Med Univ Graz, Dept Dermatol & Venerol, Graz, Austria Allergy Outpatient Clin Reumannplatz, Vienna, Austria Complejo Hosp Navarra, Serv Alergol, Pamplona, Spain Univ Amsterdam, Acad Med Ctr, Dept Expt Immunol, Amsterdam, Netherlands Univ Amsterdam, Acad Med Ctr, Dept Otorhinolaryngol, Amsterdam, Netherlands Univ Bari, Sch Med, Unit Geriatr Immunoallergol, Interdisciplinary Dept Med, Bari, Italy Complejo Hosp Univ Santiago de Compostela, Dept Allergy, Santiago De Compostela, Spain Med Univ Graz, Dept Paediat, Resp & Allerg Dis Div, Graz, Austria Charite Univ Med Berlin, Klin Dermatol Venerol & Allergol, Allergie Ctr Charite, Berlin, Germany European Innovat Partnership Act & Hlth Ageing Re, MAlad Chron Vleillissement Actif Languedoc Roussi, Paris, France INSERM, VIMA, Epidemiol & Publ Hlth Approaches, U1168,Ageing & Chron Dis, Paris, France Univ Versailles St Quentin En Yvelines, UVSQ, UMR S 1168, Versailles, France CHRU, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France Programa de Pòs‑Graduação em Pediatria e Ciências Aplicadas à Pediatria, Departamento de Pediatria EPM, Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil Web of Science
- Published
- 2016
- Full Text
- View/download PDF
5. The contact sensitizer diphenylcyclopropenone has adjuvant properties in mice and potential application in epicutaneous immunotherapy.
- Author
-
Moos, S., Johansen, P., Waeckerle-Men, Y., Mohanan, D., Senti, G., Häffner, A., and Kündig, T. M.
- Subjects
RESPIRATORY allergy ,IMMUNOLOGICAL adjuvants ,THERAPEUTICS ,IMMUNITY ,ASTHMA ,LABORATORY mice - Abstract
Background Epicutaneous vaccination has gained increasing interest during the past decade as it offers a safe, needle-free, and patient-friendly alternative to invasive vaccine administrations. Recently, the safety and early efficacy of epicutaneous immunotherapy were also demonstrated in patients with hay fever, as an alternative to conventional subcutaneous allergen-specific immunotherapy ( SCIT). One major challenge to epicutaneous vaccination is the barrier function of the stratum corneum, which must be overcome either by abrasive methods or by hydration. Such barrier function of the stratum corneum also hampers the use of common adjuvants used to enhance the efficacy of vaccination. Methods In a mouse model of allergy, we tested the adjuvant potential of diphenylcyclopropenone ( DCP), a strong contact sensitizer, which is currently used for the treatment of a T cell-mediated hair loss disease ( alopezia areata). Results Diphenylcyclopropenone enhanced antigen-specific Ig G2a antibody responses as well as IL-10 cytokine production after epicutaneous immunization with ovalbumin (OVA). Epicutaneous allergen-specific immunotherapy ( EPIT) with OVA and DCP also protected sensitized mice from anaphylaxis and asthma. The protective effect was more robust than that of conventional SCIT, which did not significantly alleviate the symptoms of allergy in the murine models of anaphylaxis and asthma. Conclusions This preclinical study confirmed previous clinical data that have demonstrated the potential of the skin as a target for allergen immunotherapy. The study also suggests that epicutaneous immunization or immunotherapy can be improved when an appropriate adjuvant such as DCP is used. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
6. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy?
- Author
-
Senti, G., von Moos, S., and Kündig, Thomas M.
- Subjects
- *
ALLERGENS , *IMMUNOTHERAPY , *RESPIRATORY allergy , *ASTHMA , *SUBLINGUAL gland , *EPIDERMIS , *ALLERGY treatment - Abstract
IgE-mediated allergies, such as allergic rhinoconjunctivitis and asthma, have become highly prevalent, today affecting up to 30% of the population in industrialized countries. Allergen-specific immunotherapy (SIT) either subcutaneously or via the sublingual route is effective, but only few patients (<5%) choose immunotherapy, as treatment takes several years and because allergen administrations are associated with local and, in some cases, even systemic allergic side-effects because of allergen accidentally reaching the circulation. In order to resolve these two major drawbacks, the ideal application site of SIT should have two characteristics. First, it should contain a high number of potent antigen-presenting cells to enhance efficacy and shorten treatment duration. Secondly, it should be nonvascularized in order to minimize inadvertent systemic distribution of the allergen and therefore systemic allergic side-effects. The epidermis, a nonvascularized multilayer epithelium, that contains high numbers of potent antigen-presenting Langerhans cells (LC) could therefore be an interesting administration route. The present review will discuss the immunological rational, history and actual clinical experience with epicutaneous allergen-specific immunotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.